Evidence map›Paper›PMID 31832401›Full record

ArticleWorld journal of clinical cases2019

Interaction of arylsulfatases A and B with maspin: A possible explanation for dysregulation of tumor cell metabolism and invasive potential of colorectal cancer.

Zsolt Kovacs, Ioan Jung, Krisztina Szalman, Laura Banias, Tivadar Jr Bara, Simona Gurzu

Open access · diamondAbstract read
In one paragraph

Article in World journal of clinical cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Zsolt KovacsDepartment of Pathology, University of Medicine, Pharmacy, Sciences and Technology "George Emil Palade", Targu Mures 530149, Romania.
Ioan JungDepartment of Pathology, University of Medicine, Pharmacy, Sciences and Technology "George Emil Palade", Targu Mures 530149, Romania.
Krisztina SzalmanDepartment of Internal Medicine, University of Medicine, Pharmacy, Sciences and Technology "George Emil Palade", Targu Mures 530149, Romania.
Laura BaniasDepartment of Pathology, University of Medicine, Pharmacy, Sciences and Technology "George Emil Palade", Targu Mures 530149, Romania.
Tivadar Jr BaraDepartment of Surgery, University of Medicine, Pharmacy, Science and Technology "George Emil Palade", Tirgu Mures 530149, Romania.
Simona GurzuDepartment of Pathology, University of Medicine, Pharmacy, Sciences and Technology "George Emil Palade", Targu Mures 530149, Romania.
Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROHai phong University Of Medicine and Pharmacy · VN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough it has been shown that arylsulfatases are lost in colorectal cancer (CRC) cell lines, their exact role in the carcinogenesis and behavior of this cancer was not elucidated. No data about the correlation between serum and immunohistochemical (IHC) level of arylsulfatases (ARSA, ARSB) in patients with CRC were published yet.

aimTo evaluate the possible prognostic value of ARSA and/or ARSB in CRC, at circulating and protein levels.

methodsThe present study included 45 consecutive patients who were prospectively diagnosed with CRC. For IHC stains (protein expression) ARSA, ARSB and maspin expression were quantified. For these markers, cytoplasmic expression was taken into account. For gene expression study, circulating mRNA was isolated from all patients, before surgery. A group of 45 healthy patients without inflammatory or tumor pathologies was used as control group. Reverse transcription and Taqman Gene Expression Array were used for

resultsThe preoperative circulating RNA level of the ARSB gene was significantly decreased in patients with CRC (RQ < 1), compared with the control group (RQ > 1). A more significant decrease (RQ < 0.5) occurred in ulcero-infiltrative maspin-positive adenocarcinomas, with a higher degree of tumor budding, diagnosed in locally advanced stages (pT3/4). ARSA/maspin immunopositivity indicated a higher risk for lymph node metastasis, while triple positivity for maspin/ARSA/ARSB and

conclusionThe significant independent negative prognostic factors of CRC are the ulcero-infiltrative aspect, high budding degree, triple positivity for maspin, ARSA and ARSB, and low ARSB gene expression.

Indexed as

ARSB geneArylsulfataseBloodColorectal cancerMaspinTissue

Identifiers

PMID31832401
PMCPMC6906558
OpenAlexW2992791058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.